Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

Genes Chromosomes and Cancer

Volumn 53, Issue 1, 2014, Pages 106-116

  Sarkozy, Clémentine ^a   Terré, Christine ^b   Jardin, Fabrice ^c   Radford, Isabelle ^d   Roche Lestienne, Catherine ^e   Penther, Dominique ^f   Bastard, Christian ^f   Rigaudeau, Sophie ^a   Pilorge, Sylvain ^a   Morschhauser, Franck ^e   Bouscary, Didier ^g   Delarue, Richard ^d   Farhat, Hassan ^a   Rousselot, Philippe ^a   Hermine, Olivier ^d   Tilly, Hervé ^c   Chevret, Sylvie ^h   Castaigne, Sylvie ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f ROUEN UNIVERSITY HOSPITAL   (France)

^g Cochin Hospital AP HP ^*  (France)

^h SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL STRUCTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; FEMALE; FOLLOW UP; HUMAN; INDOLENT MANTLE CELL LYMPHOMA; KARYOTYPE; LYMPH NODE; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLENOMEGALY;

BLASTOIDEA;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; FEMALE; HUMANS; KARYOTYPE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84887620215     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22123     Document Type: Article

References (37)

1. Beà S, Salaverria I, Armengol L, Pinyol M, Fernández V, Hartmann EM, Jares P, Amador V, Hernández L, Navarro A, Ott G, Rosenwald A, Estivill X, Campo E. 2009. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 113:3059-3069.
2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. 2011. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019-5032.
3. Carvajal-Cuenca A, Sua LF, Silva NM, Pittaluga S, Royo C, Song JY, Sargent RL, Espinet B, Climent F, Jacobs SA, Delabie J, Naresh KN, Bagg A, Brousset P, Warnke RA, Serrano S, Harris NL, Swerdlow SH, Jaffe ES, Campo E. 2011. In situ mantle cell lymphoma: Clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97:270-278.
4. Cortelazzo S, Ponzoni M, Ferreri AJM, Dreyling M. 2012. Mantle cell lymphoma. Crit Rev Oncol Hematol 82:78-101.
5. Cox D. 1972. Regression models and life tables. JR Stat Soc 34:187-220.
6. Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Bardi A, Piva N, Milani R, Bullrich F, Veronese ML, Croce C, Birg F, Döhner H, Hagemeijer A, Castoldi G. 1999. Cytogenetic profile of lymphoma of follicle mantle lineage: Correlation with clinicobiologic features. Blood 93:1372-1380.
7. Dreyling M, Kluin-Nelemans HC, Beà S, Hartmann E, Salaverria I, Hutter G, Perez-Galan P, Roue G, Pott C, Gouill SL, Cortelazzo S, Rule S, Hess G, Zaja F, Vitolo U, Szymczyk M, Walewski J, Ribrag V, Unterhalt M, Hermine O, Hoster E. 2011. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: Report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 52:2226-2236.
8. Espinet B, Salaverria I, Beà S, Ruiz-Xivillé N, Balagué O, Salido M, Costa D, Carreras J, Rodríguez-Vicente AE, Luís García J, Hernández-Rivas JM, Calasanz MJ, Siebert R, Ferrer A, Salar A, Carrió A, Polo N, García-Marco JA, Domingo A, González-Barca E. 2010. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer 49:439-451.
9. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, Camacho F, Bea S, Hartmann E, Amador V, Hernandez L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F. 2010. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408-1418.
10. Furtado M, Rule S. 2011. Indolent mantle cell lymphoma. Haematologica 96:1086-1088.
11. Haferlach C, Dicker F, Weiss T, Schnittger S, Beck C, Grote-Metke A, Oruzio D, Kern W, Haferlach T. 2010. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. Genes Chromosomes Cancer 49:851-859.
12. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, Xiao W, Braziel RM, Rimsza LM, Chan WC, Weisenburger DD, Delabie J, Jaffe ES, Gascoyne RD, Dave SS, Mueller-Hermelink HK, Staudt LM, Ott G, Beà S, Rosenwald A. 2010. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 116:953-961.
13. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M. 2008. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565.
14. Jardin F, Picquenot JM, Parmentier F, Ruminy P, Cornic M, Penther D, Bertrand P, Lanic H, Cassuto O, Humbrecht C, Lemasle E, Wautier A, Bastard C, Tilly H. 2009. Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: Clinicopathological relevance and prognosis value. Br J Haematol 146:607-618.
15. Jares P, Colomer D, Campo E. 2007. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 7:750-762.
16. Jares P, Colomer D, Campo E. 2012. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 122:3416-3423.
17. Jarosová M, Papajík T, Holzerová M, Dusek L, Pikalová Z, Lakomá I, Raida L, Faber E, Divoká M, Vlachová S, Prekopová I, Novosadová A, Pospísilová H, Indrák K. 2004. High incidence of unbalanced chromosomal changes in mantle cell lymphoma detected by comparative genomic hybridization. Leuk Lymphoma 45:1835-1846.
18. Kaplan EL, Meier P. 1958. Non-parametric estimations from incomplete observations. JASA 53:457-481.
19. Katzenberger T, Kienle D, Stilgenbauer S, Höller S, Schilling C, Mäder U, Puppe B, Petzoldt C, Sander S, Bullinger L, Stöcklein H, Kalla J, Hartmann E, Adam P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G. 2008. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. Br J Haematol 142:538-550.
20. Kienle D, Katzenberger T, Ott G, Saupe D, Benner A, Kohlhammer H, Barth TFE, Holler S, Kalla J, Rosenwald A, Muller-Hermelink HK, Moller P, Lichter P, Dohner H, Stilgenbauer S. 2007. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 25:2770-2777.
21. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD. 2012. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119:1963-1971.
22. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, DiLiberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. 2009. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209-1213.
23. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A, Stamatopoulos K, Beà S, Campo E. 2012. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 72:5307-5316.
24. Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. 2003. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 34:1030-1034.
25. Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B. 2012. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 119:4215-4223.
26. Ondrejka SL, Lai R, Smith SD, Hsi ED. 2011. Indolent mantle cell leukemia: A clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96:1121-1127.
27. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, Catovsky D, Thomas PW, Avet-Loiseau H, Oscier D. 2003. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101:4975-4981.
28. Rosenwald A, Ott G. 2008. Is there still a point for classical cytogenetic banding analysis in the diagnostic work-up of specimens suspicious for lymphoma? Leuk Lymphoma 49:6-7.
29. Royo C, Navarro A, Clot G, Salaverria I, Giné E, Jares P, Colomer D, Wiestner A, Wilson WH, Vegliante MC, Fernandez V, Hartmann EM, Trim N, Erber WN, Swerdlow SH, Klapper W, Dyer MJ, Vargas-Pabón M, Ott G, Rosenwald A, Siebert R, López-Guillermo A, Campo E, Beà S. 2012. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 26:1895-1898.
30. Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Beà S. 2011. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 21:322-334.
31. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martín-Subero JI, Nieländer I, Garcia-Conde J, Dyer MJS, Terol MJ, Pinkel D, Martinez-Climent JA. 2005. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105:4445-4454.
32. Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E, Ott G, Wright G, Lopez-Guillermo A, Chan WC, Weisenburger DD, Gascoyne RD, Grogan TM, Delabie J, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Rosenwald A, Campo E. 2007. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 25:1216-1222.
33. Salido M, Baró C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, Traverse-Glehen A, Berger F, Felman P, Thieblemont C, Gesk S, Athanasiadou A, Davis Z, Gardiner A, Milla F, Ferrer A, Mollejo M, Calasanz MJ, Florensa L, Espinet B, Luño E, Wlodarska I, Verhoef G, García-Granero M, Salar A, Papadaki T, Serrano S, Piris MA, Solé F. 2010. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: A multicenter study of the Splenic B-Cell Lymphoma Group. Blood 116:1479-1488.
34. Shaffer L, Slovak ML, Campbell LJ. 2009. ISCN 2009: An International System for Cytogenetic Nomenclature. Basel; Unionville, CT: Karger.
35. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein A, Thiele J, Vardiman JW. 2008. Mantle Cell Lymphoma. International Agency for Research on Cancer. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press.
36. Wang X, Asplund AC, Porwit A, Flygare J, Smith CIE, Christensson B, Sander B. 2008. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: Correlation to overall survival. Br J Haematol 143:248-252.
37. Wlodarska I, Pittaluga S, Hagemeijer A, De Wolf-Peeters C, Van Den Berghe H. 1999. Secondary chromosome changes in mantle cell lymphoma. Haematologica 84:594-599.